Circulating endothelial and progenitor cells in age-related macular degeneration

Abstract

Purpose:

To evaluate circulating endothelial and circulating progenitor cells as biomarkers in age-related macular degeneration patients (both exudative and atrophic forms) in order to establish the possible clinical implication of their assessment.

Methods:

We have enrolled 44 age-related macular degeneration patients: 22 patients with a recently diagnosed exudative (neovascular) form (Group A) and 22 patients with an atrophic (dry) form (Group B). The control group consisted of 22 age and sex-matched healthy subjects (Group C). The number of circulating endothelial progenitor cells (CD34+/KDR+, CD133+/KDR+, and CD34+/KDR+/CD133+), circulating progenitor cells (CD34+, CD133+, and CD34+/CD133+), and circulating endothelial cells were determined in the peripheral venous blood samples by flow cytometry. Neovascular age-related macular degeneration patients were evaluated at baseline and 4 weeks after a loading phase of three consequent intravitreal injections of ranibizumab.

Results:

Comparing age-related macular degeneration patients with the control group, endothelial progenitor cell and circulating progenitor cell levels were not significantly different, while age-related macular degeneration patients showed significantly higher levels of circulating endothelial cells (p = 0.001). Anti–vascular endothelial growth factor treatment with intravitreal ranibizumab was associated with a significant reduction of endothelial progenitor cell levels, with no significant influence on circulating progenitor cells and circulating endothelial cells.

Conclusion:

We reported higher levels of circulating endothelial cells in age-related macular degeneration patients in comparison with the control group, thereby supporting the hypothesis of an involvement of endothelial dysregulation in the age-related macular degeneration and a reduction of the endothelial progenitor cell level in neovascular age-related macular degeneration patients after three intravitreal injections of ranibizumab.

Keywords

Get full access to this article

View all access options for this article.

References

Vingerling

Dielemans

Hofman

, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 1995; 102(2): 205–210.

Congdon

O’Colmain

Klaver

, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004; 122(4): 477–485.

De Jong

. Age-related macular degeneration. N Engl J Med 2006; 355(14): 1474–1485.

Asahara

Murohara

Sullivan

, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275(5302): 964–967.

Asahara

Masuda

Takahashi

, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85(3): 221–228.

Crosby

Kaminski

Schatteman

, et al. Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res 2000; 87(9): 728–730.

Tepper

Capla

Galiano

, et al. Adult vasculogenesis occurs through in situ recruitment, proliferation, and tubulization of circulating bone marrow-derived cells. Blood 2005; 105(3): 1068–1077.

Heeschen

Aicher

Lehmann

, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003; 102(4): 1340–1346.

Rafii

Meeus

Dias

, et al. Contribution of marrow-derived progenitors to vascular and cardiac regeneration. Semin Cell Dev Biol 2002; 13(1): 61–67.

10.

Stoll

Migliorini

Kadambi

, et al. A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy. Blood 2003; 102(7): 2555–2561.

11.

Sengupta

Caballero

Mames

, et al. The role of adult bone marrow-derived stem cells in choroidal neovascularization. Invest Ophthalmol Vis Sci 2003; 44(11): 4908–4913.

12.

Espinosa-Heidmann

Reinoso

Pina

, et al. Quantitative enumeration of vascular smooth muscle cells and endothelial cells derived from bone marrow precursors in experimental choroidal neovascularization. Exp Eye Res 2005; 80(3): 369–378.

13.

Grant

May

Caballero

, et al. Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat Med 2002; 8(6): 607–612.

14.

Csaky

Baffi

Byrnes

, et al. Recruitment of marrow-derived endothelial cells to experimental choroidal neovascularization by local expression of vascular endothelial growth factor. Exp Eye Res 2004; 78(6): 1107–1116.

15.

Sheridan

Rice

Hiscott

, et al. The presence of AC133-positive cells suggests a possible role of endothelial progenitor cells in the formation of choroidal neovascularization. Invest Ophthalmol Vis Sci 2006; 47(4): 1642–1645.

16.

Yodoi

Sasahara

Kameda

, et al. Circulating hematopoietic stem cells in patients with neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2007; 48(12): 5464–5472.

17.

Machalinska

Safranow

Dziedziejko

, et al. Different populations of circulating endothelial cells in patients with age-related macular degeneration: a novel insight into pathogenesis. Invest Ophthalmol Vis Sci 2011; 52(1): 93–100.

18.

Thill

Strunnikova

Berna

, et al. Late outgrowth endothelial progenitor cells in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci 2008; 49(6): 2696–2708.

19.

Martin

Maguire

Ying

, et al. CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364(20): 1897–1908.

20.

Solomon

Lindsley

Vedula

, et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2014; 8: CD005139.

21.

Yang

Zhao

Sun

Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther 2016; 10: 1857–1867.

22.

Rayess

Rahimy

Storey

, et al. Postinjection endophthalmitis rates and characteristics following intravitreal bevacizumab, ranibizumab, and aflibercept. Am J Ophthalmol 2016; 165: 88–93.

23.

Stein

Newman-Casey

Mrinalini

, et al. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration. Ophthalmology 2014; 121(4): 936–945.

24.

Mancia

Grassi

The new European Society of Hypertension/European Society of Cardiology (ESH/ESC) guidelines. Ther Adv Cardiovasc Dis 2008; 2(1): 5–12.

25.

American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014; 37(Suppl. 1): S81–S90.

26.

Liao

Kwon

Shaughnessy

, et al. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 2004; 27(4): 978–983.

27.

Cesari

Sofi

Gori

, et al. Physical activity and circulating endothelial progenitor cells: an intervention study. Eur J Clin Invest 2012; 42(9): 927–932.

28.

Haefliger

Flammer

Beny

, et al. Endothelium-dependent vasoactive modulation in the ophthalmic circulation. Prog Retin Eye Res 2001; 20(2): 209–225.

29.

Lip

Blann

Hope-Ross

, et al. Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction. Ophthalmology 2001; 108(4): 705–710.

30.

Erdbruegger

Haubitz

Woywodt

Circulating endothelial cells: a novel marker of endothelial damage. Clin Chim Acta 2006; 373(1–2): 17–26.

31.

Say

Melamud

Esserman

, et al. Comparative analysis of circulating endothelial progenitor cells in age-related macular degeneration patients using automated rare cell analysis (ARCA) and fluorescence activated cell sorting (FACS). PLoS ONE 2013; 8(1): e55079.

32.

Scotti

Maestroni

Palini

, et al. Endothelial progenitor cells and response to ranibizumab in age-related macular degeneration. Retina 2014; 34(9): 1802–1810.

33.

Hristov

Weber

Endothelial progenitor cells in vascular repair and remodeling. Pharmacol Res 2008; 58(2): 148–151.

34.

Sasahara

Otani

Yodoi

, et al. Circulating hematopoietic stem cells in patients with idiopathic choroidal neovascularization. Invest Ophthalmol Vis Sci 2009; 50(4): 1575–1579.

35.

Chan-Ling

Baxter

Afzal

, et al. Hematopoietic stem cells provide repair functions after laser-induced Bruch’s membrane rupture model of choroidal neovascularization. Am J Pathol 2006; 168(3): 1031–1044.

36.

Vasa

Fichtlscherer

Aicher

, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89(1): E1–E7.

37.

Cuadrado-Godia

Regueiro

Nunez

, et al. Endothelial progenitor cells predict cardiovascular events after atherothrombotic stroke and acute myocardial infarction. A PROCELL substudy. PLoS ONE 2015; 10(9): e0132415.

38.

King

McDermott

JH.

Endothelial progenitor cells and cardiovascular disease. J Stem Cells 2014; 9(2): 93–106.

39.

Lee

Kim

, et al. Circulating endothelial progenitor cell levels predict cardiovascular events in end-stage renal disease patients on maintenance hemodialysis. Nephron 2015; 130(3): 151–158.

40.

Winnik

Lohmann

Siciliani

, et al. Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis—implications for cardiovascular safety. Int J Cardiol 2013; 168(3): 2453–2461.

41.

Manresa

Mulero

Losada

, et al. Influence of anti-VEGF about cardiovascular biomarkers in age related macular degeneration. J Nutr Health Aging 2015; 19(2): 228–231.

42.

Tolentino

Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011; 56(2): 95–113.

43.

Moja

Lucenteforte

Kwag

, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2014; 9: CD011230.

44.

Thulliez

Angoulvant

LeLez

, et al. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. JAMA Ophthalmol 2014; 132(11): 1317–1326.

45.

Mikačić

Bosnar

Intravitreal bevacizumab and cardiovascular risk in patients with age-related macular degeneration: systematic review and meta-analysis of randomized controlled trials and observational studies. Drugsaf 2016; 39(6): 517–541.

46.

Sengupta

Caballero

Mames

, et al. Preventing stem cell incorporation into choroidal neovascularization by targeting homing and attachment factors. Invest Ophthalmol Vis Sci 2005; 46(1): 343–348.

47.

Fadini

Baesso

Albiero

, et al. Technical notes on endothelial progenitor cells: ways to escape from the knowledge plateau. Atherosclerosis 2008; 197(2): 496–503.

48.

Zehetner

Kirchmair

Huber

, et al. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol 2013; 97(4): 454–459.

49.

Carneiro

Costa

Falcão

, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol 2012; 90(1): e25–e30.

50.

Bhisitkul

RB.

Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol 2006; 90(12): 1542–1547.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.13 MB